Literature DB >> 11866132

Pathogenesis and immune response in Atlantic salmon (Salmo salar L.) parr experimentally infected with salmon pancreas disease virus (SPDV).

L Desvignes1, C Quentel, F Lamour, Ven A le.   

Abstract

Atlantic salmon parr were injected intraperitoneally with salmon pancreas disease virus (SPDV) grown on CHSE-214 cells. The viraemia, the histopathological changes in target organs and some immune parameters were taken at intervals up to 30 days post-infection (dpi). The earliest kind of lesion was necrosis of exocrine pancreas, appearing as soon as 2 dpi. It progressed towards complete tissue breakdown at 9 dpi before resolving gradually. Concurrent to this necrosis, a strong inflammatory response was in evidence from 9 dpi in the pancreatic area for a majority of fish. A necrosis of the myocardial cells of the ventricle occurred in infected fish mainly at 16 dpi and it faded thereafter. The monitoring of the plasma viral load showed a rapid haematogenous spreading of SPDV, peaking at 4 dpi, but also the absence of a secondary viraemia. No interferon (IFN) was detected following the infection of parr with SPDV, probably owing to an IFN activity in Atlantic salmon below the detection level of the technique. Neutralising antibodies against SPDV were in evidence from 16 dpi and they showed a time-related increasing titre and prevalence. The phagocytic activity in head-kidney leucocytes was always significantly higher in the infected fish than in the control fish, being particularly high by 9 dpi. Lysozyme and complement levels were both increased and they peaked significantly in the infected fish at 9 and 16 dpi respectively. These results demonstrated that an experimental infection of Atlantic salmon parr with SPDV provoked a stimulation of both specific and non-specific immunity with regards to the viraemia and the histopathology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11866132     DOI: 10.1006/fsim.2001.0356

Source DB:  PubMed          Journal:  Fish Shellfish Immunol        ISSN: 1050-4648            Impact factor:   4.581


  6 in total

1.  Alpha interferon and not gamma interferon inhibits salmonid alphavirus subtype 3 replication in vitro.

Authors:  Cheng Xu; Tz-Chun Guo; Stephen Mutoloki; Øyvind Haugland; Inderjit S Marjara; Øystein Evensen
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

2.  No influence of oxygen levels on pathogenesis and virus shedding in Salmonid alphavirus (SAV)-challenged Atlantic salmon (Salmo salar L.).

Authors:  Linda Andersen; Kjartan Hodneland; Are Nylund
Journal:  Virol J       Date:  2010-08-21       Impact factor: 4.099

3.  Low temperature-dependent salmonid alphavirus glycoprotein processing and recombinant virus-like particle formation.

Authors:  Stefan W Metz; Femke Feenstra; Stephane Villoing; Marielle C van Hulten; Jan W van Lent; Joseph Koumans; Just M Vlak; Gorben P Pijlman
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

4.  Gene expression studies of host response to Salmonid alphavirus subtype 3 experimental infections in Atlantic salmon.

Authors:  Cheng Xu; Tz-Chun Guo; Stephen Mutoloki; Oyvind Haugland; Oystein Evensen
Journal:  Vet Res       Date:  2012-11-01       Impact factor: 3.683

5.  Vaccine Adjuvants in Fish Vaccines Make a Difference: Comparing Three Adjuvants (Montanide ISA763A Oil, CpG/Poly I:C Combo and VHSV Glycoprotein) Alone or in Combination Formulated with an Inactivated Whole Salmonid Alphavirus Antigen.

Authors:  Hanna L Thim; Stéphane Villoing; Marian McLoughlin; Karen Elina Christie; Søren Grove; Petter Frost; Jorunn B Jørgensen
Journal:  Vaccines (Basel)       Date:  2014-03-25

6.  Gene expression comparison of resistant and susceptible Atlantic salmon fry challenged with Infectious Pancreatic Necrosis virus reveals a marked contrast in immune response.

Authors:  Diego Robledo; John B Taggart; Jacqueline H Ireland; Brendan J McAndrew; William G Starkey; Chris S Haley; Alastair Hamilton; Derrick R Guy; Jose C Mota-Velasco; Almas A Gheyas; Alan E Tinch; David W Verner-Jeffreys; Richard K Paley; Georgina S E Rimmer; Ian J Tew; Stephen C Bishop; James E Bron; Ross D Houston
Journal:  BMC Genomics       Date:  2016-04-11       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.